Disposition and metabolism of Ro 24-4736 in the rat.
Ro 24-4736, a new platelet activating factor antagonist, is currently under preclinical and clinical development. The tissue distribution of the 14C-label in male rats following a single intravenous dose of 1.0 mg/kg of 14C-Ro 24-4736 indicated appreciable uptake by the liver, kidney, heart and gastrointestinal tract. Peak plasma and tissue concentrations were seen at 5 minutes after dosing except for the small intestine (4 hrs) and abdominal fat, stomach and large intestine (4 hrs). Thereafter, the 14C-label rapidly declined in all tissues. At 48 hours, only 3.5% of the dose was present in the tissues, and 6.1% in the lumen of the gastrointestinal tracts. The excretion of 14C was essentially completed; 94% of the administered 14C was excreted in the feces and 4.0% in the urine. Overall recoveries of the administered 14C label ranged from 96 to 116%. The purified major 14C-labelled component in the fecal extracts yielded essentially the same NMR spectrum as authentic Ro 24-4736 which accounted for 11% of the dose. In vitro incubations of Ro 24-4736 with rat liver 9S supernatant in an NADPH generating system produced two metabolites. NMR spectra indicated that one metabolite was hydroxylated at carbon-1 while the other one contained a hydroxyl at carbon-10 of the parent molecule. Interestingly, the sites of hydroxylation were at carbons C1, and C10 bearing the protons guarding the bay area of the phenanthrenoid ring, rather than carbons of the phenyl-methyl-thienotriazolodiazepine moiety.
Anastasi
E M
EM
Department of Drug Metabolism and Pharmacokinetics, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Williams
T H
TH
Sasso
G J
GJ
Chang
D
D
Liberato
D J
DJ
Loh
A C
AC
D000818:Animals; D001711:Biotransformation; D002250:Carbon Radioisotopes; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D013058:Mass Spectrometry; D010617:Phenanthridines / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics; D010634:Phenobarbital / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011865:Radioisotope Dilution Technique; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D014227:Triazines / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics
D002250:Carbon Radioisotopes; D010617:Phenanthridines; D010972:Platelet Activating Factor; D014227:Triazines; C071318:Ro 24-4736; D010634:Phenobarbital